Anti-CTLA-4 Antibody Conjugate Activated by Tumor Microenvironment
Summary
The USPTO has published a patent application (US20260085118A1) for a novel conjugate of an anti-CTLA-4 antibody activated by the tumor microenvironment. The application details a dual-activated conjugate designed to improve targeting efficacy, overcome drug resistance, and reduce toxicity.
What changed
This document is a patent application (US20260085118A1) filed with the USPTO, detailing a novel conjugate of an anti-CTLA-4 antibody that is activated by the tumor microenvironment. The conjugate, described by the structure R1-R2-R3-L-R4-S-cys-R5, aims to enhance the targeting capabilities of anti-CTLA-4 antibodies while mitigating drug resistance and reducing overall toxicity.
As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on entities. However, it signifies potential future developments in cancer therapeutics. Companies involved in drug development, particularly in oncology and immunotherapy, should monitor the progress of this patent application and related intellectual property as it may impact their research and development strategies or competitive landscape.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CONJUGATE OF ANTI-CTLA-4 ANTIBODY ACTIVATED BY TUMOR MICROENVIRONMENT AND USE THEREOF
Application US20260085118A1 Kind: A1 Mar 26, 2026
Inventors
Chen LIU, Yuan LIU
Abstract
A conjugate of an anti-CTLA-4 antibody activated by a tumor microenvironment and an application thereof. The conjugate has the following structure: R1-R2-R3-L-R4-S-cys-R5, wherein R1, R2, R3, L, R4, and R5 each represent structures such as different functional groups, linkers, chemical bonds, and CTLA-4 antibodies. The conjugate is a dual-activated conjugate, which can improve the targeting efficacy of the anti-CTLA-4 antibody while overcoming the drug resistance of the antibody and reducing toxicity.
CPC Classifications
C07K 16/2818 A61K 47/60 A61K 47/65 A61P 35/00 A61K 2039/505
Filing Date
2023-06-14
Application No.
18875448
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.